ArticleJournal of orthopaedic translation2025
Chronic expanding hematomas arising over a decade post primary total hip arthroplasty.
Article in Journal of orthopaedic translation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A study on the feasibility and initial outcomes of artificial intelligence-assisted preoperative planning for hip revision surgery.Frontiers in surgery · 2026Article
- From scientific discovery to orthopaedic clinical innovation.Journal of orthopaedic translation · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Chronic expanding hematoma (CEH) is an infrequent yet serious complication following total hip arthroplasty (THA). Mismanagement of this condition can result in severe consequences. The purpose of this study is to conduct a retrospective analysis of patients who developed CEH after THA at our institution over the past 20 years, complemented by a review of the existing literature. This comprehensive approach aims to contribute valuable clinical insights into the diagnosis and management of CEH. Methods: In this study, we conducted a retrospective study of patients who had undergone THA within the past two decades and subsequently developed CEH during their follow-up period at our institution. The data collected encompassed fundamental patient demographics, including age, gender, and specifics regarding the primary THA implants. Additionally, we gathered preoperative, postoperative, and follow-up imaging studies. Following the data compilation, a thorough literature review was performed to aggregate and analyze the published cases of CEH occurring post-THA. Results: Our follow-up data identified five patients who developed CEH more than ten years after undergoing THA. In one case, CEH manifested subsequent to a traumatic event, while the remaining four cases were non-traumatic. The outcomes following revision surgery were heterogeneous: two patients showed no indications of recurrence throughout a least follow-up period of over one year, one patient eventually underwent amputation, and two patients developed periprosthetic joint infection (PJI), an ongoing management challenge. Our literature review revealed nine previously reported cases with similar clinical features. A summary is as follows: Conclusion: CEH is a rare complication that can arise following THA, typically exhibiting a slow progression over a period of years. Given the potential for devastating consequences if mishandled, vigilant follow-up care is essential to ensure timely identification and immediate treatment of CEH upon detection. The translational potential of this article: This study enhances diagnostic accuracy, optimizes treatment, improves prognosis, reduces medical costs, and promotes the update of guidelines for the rare disease CEH after THA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.